{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:17:18Z","timestamp":1781709438943,"version":"3.54.5"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Lowering LDL-C has been shown to reduce ASCVD events, yet many ASCVD patients do not achieve their guideline-directed LDL-C goals leaving patients at increased risk of another ASCVD event. This review discusses implementation strategies to improve guideline-directed lipid management in patients with ASCVD focusing on the provider, patient, and system level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>At a provider level, under-prescribing of statin intensity due most often to statin intolerance, clinical inertia, insufficient monitoring of LDL-C levels, and the difficulty and cost of prescribing other lipid-lowering therapies such as the PCSK9 inhibitors leads to suboptimal cholesterol management in ASCVD patients. Patients concerns about medication side effects and lack of understanding of their ASCVD risk are causes of poor adherence to their lipid-lowering therapy as are barriers at a system level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>To improve cholesterol management in ASCVD patients will require an integrated approach targeting the provider, the patient and the system. There is a need for further education of clinicians on the importance of intensive LDL-C lowering in ASCVD patients and greater use of nonstatin LDL-C-lowering therapies for those patients on a maximally tolerated statin who have not achieved their guideline-directed LDL-C goal. This will require shared decision-making with a focus on patient education and patient\u2013clinician communication so that the clinician's goals and aims align with that of the patient.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000896","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:01:13Z","timestamp":1692342073000},"page":"252-258","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease"],"prefix":"10.1097","volume":"34","author":[{"given":"Dean G.","family":"Karalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.118.037137","article-title":"Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction: the ARIC Community Surveillance Study","volume":"139","author":"Arora","year":"2019","journal-title":"Circulation"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018\u200aAHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2\u200ayears in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the US","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"11353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"R17-20250729","first-page":"40","article-title":"Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial","volume":"6","author":"Adusumalli","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.123.064226","article-title":"Cluster randomized trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic cardiovascular disease (PCDS Statin)","volume":"147","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","article-title":"Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention","volume":"76","author":"Sud","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","article-title":"Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification","volume":"135","author":"Rana","year":"2022","journal-title":"Am J Med"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/jcm10173828","article-title":"Trends in PCSK9 inhibitor prescriptions from before and after the price reduction in patients with atherosclerotic cardiovascular disease","volume":"10","author":"Smith","year":"2021","journal-title":"J Clin Med"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","article-title":"Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic","volume":"17","author":"Chiou","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","article-title":"Real-world utilization of bempedoic acid in an academic preventive cardiology practice","volume":"16","author":"Warden","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the USAGE Study","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.amjcard.2018.12.031","article-title":"Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (a survey of US practice in the PALM registry)","volume":"123","author":"Lowenstern","year":"2019","journal-title":"Am J Cardiol"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","article-title":"Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017","volume":"140","author":"Khera","year":"2019","journal-title":"Circulation"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2015.14850","article-title":"Effect of financial incentives to physicians, patients, or both on lipid levels","volume":"314","author":"Asch","year":"2015","journal-title":"JAMA"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/clc.23448","article-title":"Is race or ethnicity associated with under-utilization of statins among women in the United States: the study of women's health across the nation","volume":"43","author":"Jackson","year":"2020","journal-title":"Clin Cardiol"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"e014709","DOI":"10.1161\/JAHA.119.014709","article-title":"Effects of race on statin prescribing for primary prevention with high atherosclerotic cardiovascular disease risk in a large healthcare system","volume":"8","author":"Dorsch","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ahj.2021.08.017","article-title":"Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program","volume":"243","author":"Plutzky","year":"2022","journal-title":"Am Heart J"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/jep.13451","article-title":"Community pharmacist interventions to improve adherence to lipid lowering medication and their influence on clinical outcomes: a systematic review and meta-analysis","volume":"27","author":"Onatibia-Astibia","year":"2021","journal-title":"J Eval Clin Pract"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2022.07.009","article-title":"Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome","volume":"16","author":"Garcia","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/HYPERTENSIONAHA.120.15946","article-title":"Healthcare delivery interventions for hypertension management in underserved populations in the United States: a systematic review","volume":"78","author":"Pasha","year":"2021","journal-title":"Hypertension"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/cd21-0029","article-title":"Quality improvement in diabetes care: a review of initiatives and outcomes in the T1D exchange quality improvement collaborative","volume":"39","author":"Ginnard","year":"2021","journal-title":"Clin Diabetes"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"e030290","DOI":"10.1136\/bmjopen-2019-030290","article-title":"Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolemia: a quantitative evidence synthesis","volume":"9","author":"Kinnear","year":"2019","journal-title":"BMJ Open"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:05:15Z","timestamp":1753826715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000896","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}